Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Healthtrust
US Department of Justice
Queensland Health
AstraZeneca
Argus Health

Generated: September 19, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,481,639

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,481,639 protect, and when does it expire?

Patent 9,481,639 protects SEYSARA and is included in one NDA.

This patent has eleven patent family members in nine countries.

Summary for Patent: 9,481,639
Title:Substituted tetracycline compounds for treatment of inflammatory skin disorders
Abstract: Methods and compositions for the treatment of skin disorders (e.g., acne, rosacea) are described.
Inventor(s): Assefa; Haregewein (Braintree, MA), Bhatia; Beena (Mansfield, MA), Draper; Michael P. (Windham, NH), Honeyman; Laura (Etobicoke, CA), Kim; Oak K. (Cambridge, MA), Molnar; Dennis P. (Hopkinton, MA)
Assignee: Paratek Pharmaceuticals, Inc. (Boston, MA)
Application Number:13/987,655
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 9,481,639

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Almirall SEYSARA sarecycline hydrochloride TABLET;ORAL 209521-001 Oct 1, 2018 RX Yes No ➤ Sign Up ➤ Sign Up A METHOD FOR TREATING ACNE IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING SARECYCLINE HYDROCHLORIDE IN 60 MG, 100 MG OR 150 MG EQUIVALENT DOSES ➤ Sign Up
Almirall SEYSARA sarecycline hydrochloride TABLET;ORAL 209521-002 Oct 1, 2018 RX Yes No ➤ Sign Up ➤ Sign Up A METHOD FOR TREATING ACNE IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING SARECYCLINE HYDROCHLORIDE IN 60 MG, 100 MG OR 150 MG EQUIVALENT DOSES ➤ Sign Up
Almirall SEYSARA sarecycline hydrochloride TABLET;ORAL 209521-003 Oct 1, 2018 RX Yes Yes ➤ Sign Up ➤ Sign Up A METHOD FOR TREATING ACNE IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING SARECYCLINE HYDROCHLORIDE IN 60 MG, 100 MG OR 150 MG EQUIVALENT DOSES ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Cantor Fitzgerald
Julphar
Cipla
McKinsey
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.